Literature DB >> 77257

Immune competence in a patient with Hodgkin's disease and relapsing toxoplasmosis.

J K Frenkel, M Amare, W Larsen.   

Abstract

A 40 year old woman with Hodgkin's disease twice developed signs of encephalitis while being treated with prednisone and cyclophosphamide for 10 months. Since on both occasions her Toxoplasma dye test titer was 1 : 8000 or higher, she was treated on suspicion of toxoplasmosis with sulfadizine and pyrimethamine. Her tumor therapy was changed to bleomycin with lower doses of prednisone for 12 months. After death from central pontine myelinolysis, Toxoplasma and cytomegalovirus could be isolated, but no lesions attributable to these infectious agents were present. Maintenance of the patient's immune competence suggested an inquiry into the effects of the chemotherapeutic agents and of tumor infiltration for their respective interference with immunity. Using hamsters with chronic latent toxoplasmosis, it was found that both cortisone and cyclophosphamide caused recrudescence of chronic inapparent infection, that vinblastine and bleomycin interfered only slightly with the development of immunity, whereas in infiltrating lymphoma permitted immunity to develop normally. It is concluded that greater attention should be directed to the immunosuppressive effects of tumor treatment. By choice of an effective tumor therapy which is least immunosuppressive, and if necessary under cover of antimicrobial therapy, a patient with Hodgkin's disease can be aided in developing immunities which he may subsequently be able to maintain.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 77257     DOI: 10.1007/BF01642165

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  36 in total

1.  CENTRAL PONTINE MYELINOLYSIS IN A 7-YEAR-OLD BOY.

Authors:  J J KEPES; C A REECE; D K OXLEY
Journal:  J Neurol Neurosurg Psychiatry       Date:  1965-02       Impact factor: 10.154

2.  Immunosuppressive agents in intracellular infection: besnoitiosis in hamsters.

Authors:  H R Wilson; J K Frenkel
Journal:  Infect Immun       Date:  1971-06       Impact factor: 3.441

3.  The poverty of the immunological mechanism in patients with Hodgkin's disease.

Authors:  I N DUBIN
Journal:  Ann Intern Med       Date:  1947-12       Impact factor: 25.391

4.  Toxoplasmosis in patients receiving immunosuppressive therapy.

Authors:  S N Cohen
Journal:  JAMA       Date:  1970-01-26       Impact factor: 56.272

5.  Combination chemotherapy-radiotherapy for stage 3 Hodgkin's disease. An acute leukemia group B study.

Authors:  B Hoogstraten; J F Holland; S Kramer; O J Glidewell
Journal:  Arch Intern Med       Date:  1973-03

6.  Toxoplasmosis. A complication of corticosteroid-and cyclophosphamide-treated lupus erythematosus.

Authors:  H V Dubin; M H Courter; E R Harrell
Journal:  Arch Dermatol       Date:  1971-11

7.  Generalized toxoplasmosis following renal transplantation. Report of a case.

Authors:  E S Reynolds; K W Walls; R I Pfeiffer
Journal:  Arch Intern Med       Date:  1966-10

8.  Toxoplasmosis mimicking a brain abscess in an adult with treated scleroderma.

Authors:  C R Bamford
Journal:  Neurology       Date:  1975-04       Impact factor: 9.910

9.  Effects of corticosteroids on antibody and immunity in Besnoitia infection of hamsters.

Authors:  J K Frenkel; M N Lunde
Journal:  J Infect Dis       Date:  1966-10       Impact factor: 5.226

10.  Immunosuppression and toxoplasmic encephalitis: clinical and experimental aspects.

Authors:  J K Frenkel; B M Nelson; J Arias-Stella
Journal:  Hum Pathol       Date:  1975-01       Impact factor: 3.466

View more
  5 in total

1.  Diagnosis of toxoplasmosis using DNA probes.

Authors:  D Savva; R E Holliman
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

Review 2.  The antinflammatory effects of glucocorticosteroids. A brief review of the literature.

Authors:  A M Dannenberg
Journal:  Inflammation       Date:  1979-07       Impact factor: 4.092

3.  Tamoxifen Increased Parasite Burden and Induced a Series of Histopathological and Immunohistochemical Changes During Chronic Toxoplasmosis in Experimentally Infected Mice.

Authors:  Ashraf Mohamed Barakat; Hassan Ali Mohamed El Fadaly; Rabab Fawzy Selem; Abd El-Nasser A Madboli; Khaled A Abd El-Razik; Ehssan Ahmed Hassan; Ali H Alghamdi; Ehab Kotb Elmahallawy
Journal:  Front Microbiol       Date:  2022-05-30       Impact factor: 6.064

4.  Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis.

Authors:  Ze-Dong Wang; Huan-Huan Liu; Zhan-Xi Ma; Hong-Yu Ma; Zhong-Yu Li; Zhi-Bin Yang; Xing-Quan Zhu; Bin Xu; Feng Wei; Quan Liu
Journal:  Front Microbiol       Date:  2017-03-09       Impact factor: 5.640

5.  Toxoplasmosis an Overlooked Disease: Seroprevalence in Cancer Patients

Authors:  Raafat Abdel Malek; Rita Wassef; Enas Rizk; Hoda Sabry; Nevine Tadros; Abdallah Boghdady
Journal:  Asian Pac J Cancer Prev       Date:  2018-07-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.